Literature DB >> 31997570

Stabilization of the TAK1 adaptor proteins TAB2 and TAB3 is critical for optimal NF-κB activation.

Harald Braun1,2, Jens Staal1,2,3.   

Abstract

TAB2 and TAB3 bind to K63-linked polyubiquitin chains and recruit the critical kinase MAP3K7 (TAK1). The polyubiquitin-recruited TAK1/TAB2/TAB3 complex comes in close proximity with the IKK (IKKα/IKKβ/IKKγ) complex, which is recruited to M1-linked polyubiquitin chains via the IKKγ (NEMO) component. Together, the two complexes activate the NF-κB family of transcription factors. NF-κB transcription factors are critical mediators of pro-inflammatory signals and must be tightly regulated at multiple levels. Recently, it was discovered that one such point of regulation occurs at the level of TAB2 and TAB3 protein stability by the deubiquitinase USP15. Comment on: https://doi.org/10.1111/febs.15202.
© 2020 Federation of European Biochemical Societies.

Entities:  

Keywords:  epitransduction; inflammation; lysosome; proteasome; signalophagy

Mesh:

Substances:

Year:  2020        PMID: 31997570     DOI: 10.1111/febs.15210

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  3 in total

1.  microRNA-149-5p mediates the PM2.5-induced inflammatory response by targeting TAB2 via MAPK and NF-κB signaling pathways in vivo and in vitro.

Authors:  Qiuyue Li; Siling Li; Chunjie Xu; Jing Zhao; Lin Hou; Fuyang Jiang; Zhonghui Zhu; Yan Wang; Lin Tian
Journal:  Cell Biol Toxicol       Date:  2021-07-31       Impact factor: 6.691

2.  TAB2 deficiency induces dilated cardiomyopathy by promoting RIPK1-dependent apoptosis and necroptosis.

Authors:  Haifeng Yin; Xiaoyun Guo; Yi Chen; Yachang Zeng; Xiaoliang Mo; Siqi Hong; Hui He; Jing Li; Rachel Steinmetz; Qinghang Liu
Journal:  J Clin Invest       Date:  2022-02-15       Impact factor: 14.808

Review 3.  USP15 in Cancer and Other Diseases: From Diverse Functionsto Therapeutic Targets.

Authors:  Yan-Chi Li; Song-Wang Cai; Yu-Bin Shu; Mei-Wan Chen; Zhi Shi
Journal:  Biomedicines       Date:  2022-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.